Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic NK cell therapy in relapsed/refractory or high-risk multiple myeloma
IRCT20230801058996N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2023
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic natural killer cells in multiple myeloma (MM), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Percentage of adverse effect, Overall survival and 1 more. Started Jan 2023; status: completed.
02
Drugs
allogeneic natural killer cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on IRCT20230801058996N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230801058996N1.